IGF-1 LR3 (0.1mg) protocols focus on this long-acting synthetic analog of Insulin-like Growth Factor-1 (IGF-1), designed with an extended half-life to enhance biological activity. It is studied for its potential role in supporting muscle hypertrophy, recovery, nutrient utilization, and cellular growth signaling. This guide outlines a subcutaneous administration approach optimized for the 0.1 mg (100 mcg) vial format.
Concise summary of the subcutaneous regimen.
Suggested approach for the 0.1 mg vial format.
IGF-1 LR3 (Long R3 IGF-1) is a modified form of IGF-1 with reduced binding affinity to IGF-binding proteins (IGFBPs), which increases its bioavailability and prolongs activity in circulation compared to native IGF-1.
It binds to the IGF-1 receptor (IGF-1R), activating intracellular signaling pathways such as PI3K-AKT and MAPK. These pathways are associated with increased protein synthesis, muscle cell growth, and reduced protein breakdown. Due to its extended half-life, IGF-1 LR3 provides sustained receptor activation, which may enhance anabolic and recovery-related processes in muscle and connective tissues.
Observations based on preclinical and research literature.
Potential Benefits:
Possible Side Effects: